Original Source(s)
Related Content
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026